127 related articles for article (PubMed ID: 7688176)
1. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].
Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
3. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis.
Zhang LM; Jiang HW; Tong SJ; Zhu HQ; Liu J; Ding Q
Urol Int; 2013; 91(1):38-48. PubMed ID: 23774685
[TBL] [Abstract][Full Text] [Related]
5. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
6. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
8. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
9. [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
Ruiz de la Roja JC; Llorente Abarca C; Romero Cagigal I; Páez Borda A; Fernández González I; Martín Osés E; Berenguer Sánchez A
Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572
[TBL] [Abstract][Full Text] [Related]
10. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
Leo ME; Bilhartz DL; Bergstralh EJ; Oesterling JE
J Urol; 1991 Apr; 145(4):802-6. PubMed ID: 1706440
[TBL] [Abstract][Full Text] [Related]
12. Bone scan in initial staging of prostate cancer.
Boughattas S; Letaief B; Hassine H; Chatti K; Essabah H
Tunis Med; 2003 Jun; 81(6):400-6. PubMed ID: 14534946
[TBL] [Abstract][Full Text] [Related]
13. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
Int J Urol; 2007 Feb; 14(2):123-7. PubMed ID: 17302568
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
15. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy?
Warren KS; Chodak GW; See WA; Iverson P; McLeod D; Wirth M; Morris C; Armstrong J
J Urol; 2006 Jul; 176(1):70-3; discussion 73-4. PubMed ID: 16753371
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
17. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?
Sissons GR; Clements R; Peeling WB; Penney MD
Br J Radiol; 1992 Oct; 65(778):861-4. PubMed ID: 1384917
[TBL] [Abstract][Full Text] [Related]
18. The prognostic importance of prostate-specific antigen in monitoring patients undergoing maximum androgen blockage for metastatic prostate cancer.
Kiper A; Yigitbasý O; Imamoglu A; Tuygun C; Turan C
ScientificWorldJournal; 2005 Jan; 5():118-24. PubMed ID: 15702224
[TBL] [Abstract][Full Text] [Related]
19. Correlation between bone metabolic markers and bone scan in prostatic cancer.
Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
[TBL] [Abstract][Full Text] [Related]
20. [The concept of biologic progression in metastatic cancer of the prostate hormonally treated].
Morote J; Lorente JA; Vallejo C; Encabo G; López-Pacios MA; De Torres JA; Soler Roselló A
Actas Urol Esp; 1994 Jun; 18(6):666-9. PubMed ID: 7524279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]